Shares of Gland Pharma slipped 4.03% to ₹1,892.50 in Friday’s session, as investors reacted sharply to U.S. President Donald Trump’s announcement of a 100% tariff on imports of branded and patented pharmaceutical products starting October 1, 2025.
The move is expected to hit Indian pharmaceutical exporters significantly, with America being the largest market for the sector. India accounts for nearly 45% of U.S. generic supplies and 15% of biosimilars, making it one of the most exposed industries to tariff shocks. Gland Pharma, which generates a considerable portion of its revenues from the U.S. market through complex generics and injectables, is seen as vulnerable under the new tariff regime.
While Trump clarified that products from companies building or expanding manufacturing plants in the U.S. will be exempt, uncertainties remain on whether complex generics and specialty injectables — Gland’s key portfolio — will fall under scrutiny. Analysts caution that higher duties could pressure margins for companies like Gland Pharma, which already operate on tight spreads in the U.S. market.
The broader Nifty Pharma index also traded weak, reflecting the sector-wide selloff following Trump’s announcement. Market participants now await clarity on the scope of the tariffs and whether India will initiate negotiations to safeguard its $8.7 billion U.S. pharma export market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
